CD1C is associated with breast cancer prognosis and immune infiltrates.
Breast cancer
CD1C
CIBERSORT algorithm
ESTIMATE algorithm
Tumor microenvironment
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
08 Feb 2023
08 Feb 2023
Historique:
received:
02
06
2022
accepted:
18
01
2023
entrez:
9
2
2023
pubmed:
10
2
2023
medline:
11
2
2023
Statut:
epublish
Résumé
The tumor microenvironment (TME) in breast cancer plays a vital role in occurrence, development, and therapeutic responses. However, immune and stroma constituents in the TME are major obstacles to understanding and treating breast cancer. We evaluated the significance of TME-related genes in breast cancer. Invasive breast cancer (BRCA) samples were retrieved from the TCGA and GEO databases. Stroma and immune scores of samples as well as the proportion of tumor infiltrating immune cells (TICs) were calculated using the ESTIMATE and CIBERSORT algorithms. TME-related differentially expressed genes (DEGs) were analyzed by a protein interaction (PPI) network and univariate Cox regression to determine CD1C as a hub gene. Subsequently, the prognostic value of CD1C, its response to immunotherapy, and its mechanism in the TME were further studied. In BRCA, DEGs were determined to identify CD1C as a hub gene. The expression level of CD1C in BRCA patients was verified based on the TCGA database, polymerase chain reaction (PCR) results, and western blot analysis. Immunohistochemical staining (IHC) results revealed a correlation between prognosis, clinical features, and CD1C expression in BRCA. Enrichment analysis of GSEA and GSVA showed that CD1C participates in immune-associated signaling pathways. CIBERSORT showed that CD1C levels were associated with tumor immune infiltrating cells (TILs), such as different kinds of T cells. Gene co-expression analysis showed that CD1C and the majority of immune-associated genes were co-expressed in BRCA. In renal cell carcinoma, patients with a high expression of CD1C had a better immunotherapy effect. CD1C is an important part of the TME and participates in immune activity regulation in breast tumors. CD1C is expected to become a prognostic marker and a new treatment target for breast cancer.
Sections du résumé
BACKGROUND
BACKGROUND
The tumor microenvironment (TME) in breast cancer plays a vital role in occurrence, development, and therapeutic responses. However, immune and stroma constituents in the TME are major obstacles to understanding and treating breast cancer. We evaluated the significance of TME-related genes in breast cancer.
METHODS
METHODS
Invasive breast cancer (BRCA) samples were retrieved from the TCGA and GEO databases. Stroma and immune scores of samples as well as the proportion of tumor infiltrating immune cells (TICs) were calculated using the ESTIMATE and CIBERSORT algorithms. TME-related differentially expressed genes (DEGs) were analyzed by a protein interaction (PPI) network and univariate Cox regression to determine CD1C as a hub gene. Subsequently, the prognostic value of CD1C, its response to immunotherapy, and its mechanism in the TME were further studied.
RESULTS
RESULTS
In BRCA, DEGs were determined to identify CD1C as a hub gene. The expression level of CD1C in BRCA patients was verified based on the TCGA database, polymerase chain reaction (PCR) results, and western blot analysis. Immunohistochemical staining (IHC) results revealed a correlation between prognosis, clinical features, and CD1C expression in BRCA. Enrichment analysis of GSEA and GSVA showed that CD1C participates in immune-associated signaling pathways. CIBERSORT showed that CD1C levels were associated with tumor immune infiltrating cells (TILs), such as different kinds of T cells. Gene co-expression analysis showed that CD1C and the majority of immune-associated genes were co-expressed in BRCA. In renal cell carcinoma, patients with a high expression of CD1C had a better immunotherapy effect.
CONCLUSION
CONCLUSIONS
CD1C is an important part of the TME and participates in immune activity regulation in breast tumors. CD1C is expected to become a prognostic marker and a new treatment target for breast cancer.
Identifiants
pubmed: 36755259
doi: 10.1186/s12885-023-10558-2
pii: 10.1186/s12885-023-10558-2
pmc: PMC9905770
doi:
Substances chimiques
Antigens, CD1
0
CD1C protein, human
0
Glycoproteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
129Subventions
Organisme : Natural Science Foundation of Anhui Province of China
ID : Grant no.2008085QC112
Organisme : Natural Science Foundation of Anhui Province of China
ID : Grant no.2008085QC112
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023. The Author(s).
Références
Cancer Cell. 2017 May 8;31(5):711-723.e4
pubmed: 28486109
Nat Biotechnol. 2018 Apr;36(4):346-351
pubmed: 29505028
Curr Opin Immunol. 2017 Jun;46:127-133
pubmed: 28756303
Chin Clin Oncol. 2020 Jun;9(3):27
pubmed: 32192349
Front Immunol. 2020 Sep 30;11:559166
pubmed: 33101275
CPT Pharmacometrics Syst Pharmacol. 2013 Oct 16;2:e79
pubmed: 24132163
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
J Immunother Cancer. 2019 Apr 18;7(1):109
pubmed: 30999964
Int J Mol Sci. 2020 Oct 15;21(20):
pubmed: 33076281
Clin Breast Cancer. 2021 Feb;21(1):e63-e73
pubmed: 32893093
Curr Opin Immunol. 2002 Aug;14(4):503-8
pubmed: 12088686
Mol Immunol. 2013 Sep;55(2):182-5
pubmed: 23127489
Semin Oncol. 2019 Apr;46(2):121-132
pubmed: 31239068
Mol Oncol. 2013 Oct;7(5):859-69
pubmed: 23890733
Bioinformatics. 2020 Jun 1;36(11):3582-3584
pubmed: 32119082
Blood Adv. 2020 Jan 14;4(1):87-99
pubmed: 31899802
Immunol Rev. 2014 May;259(1):115-39
pubmed: 24712463
Brief Bioinform. 2021 Jul 20;22(4):
pubmed: 33302293
Bioinformatics. 2018 Jul 1;34(13):i555-i564
pubmed: 29950010
F1000Res. 2017 Oct 30;6:1909
pubmed: 29152228
J Clin Invest. 2020 Dec 1;130(12):6290-6300
pubmed: 32784290
Medicina (Kaunas). 2019 Dec 30;56(1):
pubmed: 31906017
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Cell Physiol. 2019 Jun;234(6):8509-8521
pubmed: 30520029
Methods Mol Biol. 2021;2239:269-303
pubmed: 33226625
Mol Cell Endocrinol. 2014 Jan 25;382(1):673-682
pubmed: 23791814
Oncogene. 2019 Jun;38(25):4887-4901
pubmed: 30816343
Endocr Metab Immune Disord Drug Targets. 2020;20(10):1597-1610
pubmed: 32342824
J Exp Med. 2003 Nov 3;198(9):1369-80
pubmed: 14581610
Adv Exp Med Biol. 2018;1060:99-114
pubmed: 30155624
Front Immunol. 2019 Dec 10;10:2829
pubmed: 31921114
BMC Cancer. 2014 Jan 29;14:49
pubmed: 24475985
Nat Commun. 2013;4:2612
pubmed: 24113773
Int Immunol. 1997 Jul;9(7):1061-4
pubmed: 9237115
Breast. 2013 Aug;22 Suppl 2:S50-6
pubmed: 24074793
Oncol Lett. 2018 Apr;15(4):5087-5092
pubmed: 29552142
BMC Bioinformatics. 2011 Jan 26;12:35
pubmed: 21269502
Nat Commun. 2019 Jun 7;10(1):2498
pubmed: 31175312